The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
Top Cited Papers
- 1 June 2004
- journal article
- review article
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 25 (3) , 458-511
- https://doi.org/10.1210/er.2003-0014
Abstract
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or alpha-interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.Keywords
This publication has 523 references indexed in Scilit:
- The Laboratory Diagnosis of Adrenal Pheochromocytoma: The Mayo Clinic ExperienceJournal of Clinical Endocrinology & Metabolism, 2003
- Pheochromocytoma: State-of-the-Art and Future ProspectsEndocrine Reviews, 2003
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- 7‐hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin‐producing tumorsCancer, 2002
- Primary Ovarian Carcinoid TumorsGynecologic Oncology, 1996
- The Glucagonoma Syndrome Clinical and Pathologic Features in 21 PatientsMedicine, 1996
- Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotideEuropean Journal Of Cancer, 1994
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal Of Cancer, 1992
- Palliation of malignant phaeochromocytoma with combination chemotherapyEuropean Journal Of Cancer, 1992
- Treatment of metastatic carcinoid tumour with recombinant interferon alfaEuropean Journal Of Cancer, 1992